Darbepoetin alfa + canakinumab

1 treatment and condition followed through the public trial records. Not medical advice. How a status is set

Treatments and conditions

Darbepoetin alfa + canakinumab
Treatment and conditionWhere it standsTrials
Darbepoetin alfa + canakinumab for myelodysplastic syndromesPhase 1 trial, as of 19 Nov 2026 (not yet checked by a person)1